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Introduction: Focal adhesion kinase (FAK) controls cell growth and survival downstream of integrin-matrix receptors.
Upon adhesion loss or FAK inhibition, FAK can translocate to the nucleus. The nucleolus is a non-membrane nuclear
structure that regulates ribosome biogenesis and cell proliferation. Nucleostemin (NS), a nucleolar-localized protein,
modulates cell cycle progression, stemness, and three-dimensional tumor spheroid formation. The signaling pathways
that regulate NS levels in tumors remain undefined.
Methods: Human breast carcinoma cells were evaluated for growth in culture (adherent and anchorage-independent
spheroid) and as orthotopic tumors. FAK signaling was evaluated by pharmacological FAK inhibitor addition (PF-271,
IC50 ~ 0.1 μM) and by small hairpin RNA (shRNA) knockdown followed by re-expression of FAK wildtype (WT) or a
kinase-dead (KD, K454R) FAK point mutant. Immunoblotting was used to evaluate FAK, NS, nucleolar phosphoprotein
B23, and nucleolin levels. Total and phosphospecific antibody imunoblotting were used to detect changes in FAK, Akt
kinase (Akt also known as protein kinase B), and 4E-binding protein 1 (4E-BP1) phosphorylation, a translation
repressor protein and target of the mammalian target of rapamycin (mTOR) complex. Immunohistochemical,
co-immunoprecipitation, and cellular fractionation analyses were used to evaluate FAK association with nucleoli.
Results: Pharmacological (0.1 μM PF-271) or genetic inhibition of FAK activity prevents MDA-MB-231 and 4T1L breast
carcinoma growth as spheroids and as orthotopic tumors. FAK inhibition triggers proteasome-mediated decreased NS
levels but no changes in other nucleolar proteins such as B23 (nucleophosmin) or nucleolin. Active FAK was
associated with purified nucleoli of anchorage-independent cells and present within nucleoli of human invasive
ductal carcinoma tumor samples. FAK co-immunoprecipitated with B23 that binds NS and a complex between FAK,
NS, Akt, and mTOR was detected. Constitutively-active Akt kinase promoted tumor spheroid growth, stabilized NS
levels, and promoted pS65 4E-BP1 phosphorylation in the presence of inhibited FAK. Rapamycin lowered NS levels
and inhibited pS65 4E-BP1 phosphorylation in cells with activated Akt-mTOR signaling.
Conclusions: FAK signaling occurs in the nucleolus, active FAK protects NS, and Akt-mTOR pathway regulates NS
protein stability needed for breast carcinoma spheroid and tumor growth.Introduction
Breast cancer is one of the most common cancers in
women worldwide [1]. It is a heterogeneous disease with
differential responses to therapy [2]. Triple-negative
breast cancers exhibit resistance to various chemother-
apies and are the most aggressive tumors with a 5-year
survival rate of <30% [3]. Relapse and patient mortality
results in part from tumor spread and metastasis [4].* Correspondence: dschlaepfer@ucsd.edu
1Department of Reproductive Medicine, University of California San Diego,
Moores Cancer Center, 3855 Health Sciences Dr, La Jolla, CA 92093, USA
Full list of author information is available at the end of the article
© 2015 Tancioni et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.Signals generated from transmembrane integrin recep-
tors are one of the molecular drivers of tumor metastasis
[5]. Integrins sense changes in extracellular matrix com-
position and tension and in turn activate focal adhesion
kinase (FAK), a 115 kDa cytoplasmic tyrosine kinase [6].
FAK mRNA levels are elevated in approximately 26% of
breast tumors, and high FAK protein levels are common
in human epidermal growth factor 2 (HER2)-positive [7]
and triple-negative tumors [8]. FAK overexpression is as-
sociated with increased tumor growth, an invasive
phenotype, higher histological grade, and poor patient
prognosis [8-10]. Mouse tumor models reveal that FAKl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tumor initiation and progression [11-14].
Studies evaluating genetic or pharmacological inactiva-
tion of FAK activity within tumor cells have linked FAK
signaling to the promotion of tumor growth, angio-
genesis, and tumor metastasis [6,15]. In vitro, sub-
micromolar concentrations of pharmacological FAK
inhibitors can prevent tumor cell growth under three-
dimensional but not necessarily two-dimensional con-
ditions [16-19]. This is associated with tumor cells
expressing low merlin tumor suppressor expression
and β1 and β5 integrin signaling linkages [19-21].
Tumor spheroid survival is highly dependent on FAK
activity [16,21]. These FAK-associated signals can be gen-
erated at the cell surface in association with integrins.
However, because FAK also translocates to the nucleus
when cells are grown in suspension [22], and nuclear FAK
can alter gene expression [23,24], the location for FAK-
mediated survival signal generation within tumor spher-
oids remains undefined.
It also remains unclear whether FAK activity within a
tumor spheroid impacts the expression of target proteins
selectively required for three-dimensional or anchorage-
independent cell survival. To this end, tumor spheroids
share many characteristics of cancer stem cells [25].
Several proteins associated with the nucleolus play im-
portant roles in genome protection, ribosome synthesis,
and stem cell proliferation [26,27]. Nucleostemin (NS), a
62-kDa nucleolar protein, regulates proliferation in stem
and cancer cells [28,29]. Interestingly, NS promotes
anchorage-independent mammary tumor spheroid growth
[30] and is increased during mouse mammary tumor pro-
gression [31], and breast cancer patients with NS-positive
tumors exhibit significantly shorter disease-free survival
[32]. NS is a guanine triphosphate (GTP)-binding protein
that shuttles between the nucleolus and nucleoplasm [33].
Inhibition of guanine nucleotide synthesis triggers nucle-
olar stress, NS movement to the nucleoplasm, and NS
proteasomal degradation [34,35]. Although increased
levels of reactive oxygen species can enhance NS protein
stability [36], the signaling pathways controlling NS levels
in tumor cells remain undefined.
Here, we show that FAK and NS are part of a signaling
axis promoting breast carcinoma tumor progression.
Pharmacological or genetic FAK inhibition reduces NS
levels in cells grown as tumors by regulating its stability.
FAK activity and NS are required for anchorage-
independent spheroid growth. Cell fractionation ana-
lyses revealed active FAK association with nucleoli
and a complex between FAK, NS, Akt, and mamma-
lian target of rapamycin (mTOR) was detected by co-
immunoprecipitation with green fluorescent tagged
NS. Mechanistically, activated Akt kinase expression
was sufficient to rescue effects of FAK inhibition andrapamycin treatment triggered loss of NS protein in
cells with activated Akt-mTOR signaling. Our studies
support a non-canonical role for nucleolar-associated
FAK signaling and Akt-mTOR activation in the mainten-
ance of NS protein expression.Methods
Antibodies and reagents
Antibodies to pY397 FAK (clone 141–9) were from Life
Technologies (Carlsbad, CA, USA). Antibodies to Akt
(clone C67E7), pS473 Akt (9271), mTOR (2983) and
pS65 4E-BP1 (9451) were from Cell Signaling (Beverly,
MA, USA). Antibodies to NS (70346), B23 (clone
FC82291), and pY397 FAK (4803) were from Abcam
(Cambridge, MA, USA). Anti-human nucleolin (clone
D-6) and anti-Lamin B (sc-6216) were from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Monoclonal
(clone 4.47) and polyclonal antibodies to FAK (06–543)
were from Millipore (Bedford, MA, USA). Antibodies to
β-actin (clone AC-74, Sigma) and GAPDH (clone
GT239) were Sigma (St. Louis, MO, USA) and GenTex
(Irvine, CA, USA), respectively. Monoclonal antibody
(clone B34) and polyclonal (A-6455) to GFP and were
from Covance (Princeton, NJ, USA) and Life Tech-
nologies, respectively. Plasmid pLKO.1-puro non-
target shRNA control (SHC016) was from Mission-
Sigma (St. Louis, MO, USA). Human NS shRNA lentivirus
plasmids (in pLKO.1-puro) were from Mission-Sigma
(clone IDs 206826.1-683s21c1 and 206826.1-1310s21c).
Plasmid pBabe-puro and pBabe-Puro-Myr-Flag-Akt1
(15294) were from Addgene (Cambridge, MA, USA).
MG132 and rapamycin were from Calbiochem (San Diego,
CA, USA) and LC Laboratories (Woburn, MA, USA),
respectively. PF-562,271 (PF-271) was synthesized as
described [37] and PND-1186 (renamed VS-4718 by
Verastem Inc.) was from Poniard (San Francisco, CA,
USA). For in vitro studies, PF-271 and PND-1186 were
dissolved in dimethyl sulfoxide (DMSO).Cells
The 4T1 murine mammary carcinoma cells, BT474,
MDA-MB-231 and MDA-MB-468 human breast carcin-
oma cells were from American Type Culture Collection.
MCF-7 human breast carcinoma cells were obtained
from David Cheresh (UCSD, University California San
Diego, CA, USA). Selection of highly metastatic mCherry
4T1 cells named 4T1L was performed by isolation and ex-
pansion of cells from lung metastases [15]. FAK shRNA-
expressing HEY cells (ovarian cancer cells) were gener-
ated and cultivated as described [19]. Table 1 lists source,
culture conditions, and selective DNA sequencing infor-
mation for the breast carcinoma cells used in this study.
Table 1 Background information on the breast carcinoma cell lines used in this study
Cells Source Culture media Cancer type Selected genetic events [51]
MCF7 D. Cheresh (UCSD) (1) Invasive ductal carcinoma [52] PIK3CA (E545K)
BT474 ATCC (1) Invasive ductal carcinoma [52] PIK3CA (K111N)
TP53 (E285K)
HER2 (amplification)
MDA-MB-231 ATCC (2) Adenocarcinoma [52] BRAF (G464V)
KRAS (G13D)
TP53 (R280K)
MDA-MB-468 ATCC (2) Adenocarcinoma [52] PTEN (V85_splice)
4T1L D Schlaepfer (UCSD) (2) Selection of metastatic mCherry-labeled 4 T1 cells by isolation
and culture of cells from 4 T1 lung metastases [15]
(undetermined)
(1) Roswell Park Memorial Institute medium supplemented with 10% FBS, 0.1 mM non-essential amino acids, 2 mM glutamine, 100 U/ml penicillin, and 100 μg/ml
streptomycin. (2) DMEM supplemented with 10% FBS, 0.1 mM non-essential amino acids, 2 mM glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin.
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Short-hairpin (shRNA) targeting human FAK and a
scrambled (Scr) control in pLentiLox 3.7-puro were cre-
ated as described [22]. Lentiviral transduced cells were
selected by growth in puromycin, clones were isolated
by single cell sorting, and characterized by anti-FAK im-
munoblotting as described [17]. Three cell clones were
pooled, expanded, and stored frozen as Scr- or FAK
shRNA-expressing MDA-MB-231 cells. Green fluores-
cent protein (GFP)-tagged murine FAK wildtype (WT)
or murine FAK kinase-dead (KD, K454R) in pCDH1-
MCS1-EF1-Puro (System Biosciences) were stably re-
expressed by lentiviral transduction and puromycin
selection. MDA-MB-231 FAK-WT and FAK-KD cells
were stably transduced with a myristoylated and
membrane-targeted form of Akt (Addgene) via retroviral
transduction as described [22]. Cells were transduced
with fluorescent mCherry protein (pmCherry-C1,
Clontech) using a lentivirus expression vector (pCDH-
CMV-MSC1, System Biosciences) as described [17] prior
to initiation of mouse tumor studies. Human NS was amp-
lified by PCR and subcloned into pEGFP-C1 (Clonetch)
from pBabe-NS provided by Frederic Lessard and Gerardo
Ferbeyre (Université de Montréal). MDA-MB-231 cells
were transiently transfected using jetPRIME (PolyPlus
Transfection) GFP or GFP-NS plasmid DNA (10 μg).
Cell growth
For adherent growth, 1 × 104 cells in 2 ml growth media
were distributed in 6-well plates (Costar, tissue culture
treated). Between 24 and 120 hours, all cells were col-
lected by limited trypsin-EDTA treatment, a single cell
suspension was prepared, and the viable total cell num-
ber determined by automated trypan blue staining and
counting (ViCell XR, Beckman). For three-dimensional
cultures, 10,000 cells were embedded in 1% methylcellu-
lose diluted in growth media and plated onto 6-wellpoly-hyodroxyethyl methacrylic acid (poly-HEMA)-
coated plates (Costar). At the indicated time, colonies
were imaged in phase contrast, and enumerated by
counting five different fields of each well. All experimen-
tal points were performed in triplicate and repeated at
least two times.Mice
Female NOD/SCID (Harlan Laboratories, Indianapolis,
IN, USA) mice were housed in pathogen-free conditions
according to the Association for the Assessment and
Accreditation for Laboratory Animal Care guidelines.
Studies were performed with approval of the University
of California, San Diego Institutional Animal Care and
Use Committee protocols. No body weight loss or mor-
bidity was associated with the study protocols.Mouse tumor studies
MDA-MB-231 (0.5 × 106) cells in 10 μl of growth factor-
depleted Matrigel (BD Biosciences) were injected into
the T4 mammary fat pad of 8- to 10-week-old mice
using a Hamilton syringe and a 28-gauge needle. Tu-
mors were measured every 3 to 4 days with digital ver-
nier calipers and tumor volume (mm3) was calculated
using the formula:
V ¼ axb2=2
where V = volume, a = length, mm and b = width, mm.
Sites of spontaneous lung metastasis were imaged using
the OV100 Small Animal Imaging System (Olympus) with
a set exposure and quantified by combined dorsal and ven-
tral fluorescent images using Image J (v1.46r) with a set
threshold.
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Cell lysis buffer (1% Triton X-100, 1% sodium deoxycho-
late, 0.1% SDS, 50 mM HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) pH 7.4, 150 mM NaCl,
10% glycerol, 1.5 mM MgCl2, 1 mM EGTA, 10 mM
sodium pyrophosphate, 100 mM NaF, 1 mM sodium
orthovanadate, and 10 μg/mL leupeptin) was used to ex-
tract proteins from cultured cells and tumors were ho-
mogenized (Pro 200 tissue homogenizer, Pro Scientific)
in lysis buffer without sodium deoxycholate and SDS.
Total protein levels were determined by Bradford assay
(Thermo Scientific), proteins were resolved by NuPAGE
4-12% Tris-Bis gels (Invitrogen), and transferred to poly-
vinylidene difluoride membranes (Immobilon, Millipore)
for antibody immunoblotting. Relative expression levels
and phosphospecific antibody reactivity were measured
by densitometry analyses of blots using Image J. For im-
munoprecipitation, lysates were diluted threefold in cell
lysis buffer and incubated with polyclonal anti-FAK
antibody or anti-GFP at 4°C, overnight. After incuba-
tion with protein A Plus agarose beads (Millipore)
for 1 hour at 4°C, antibodies were collected by cen-
trifugation, washed twice with cell lysis buffer and
resolved by PAGE.Nucleolar isolation
Cell fractionation to isolate nucleoli was performed
as described [38] with some modifications. Briefly,
0.5 × 107 cells were collected by trypsinization and
processed, or plated onto poly-HEMA-coated plates
for 4 hours prior to processing. Cells were lysed using a
hypotonic solution (10 mM HEPES pH 7.9, 10 mM KCl,
1.2 mM MgCl2, 0.3% NP-40 and 0.5 mM dithiothreitol)
and dounce homogenized with a tight pestle. Intact
nuclei were pelleted by centrifugation (228 × g for
5 minutes) and the cytoplasmic supernatant saved
and stored frozen at −20°C. Nuclei were resuspended
in 0.25 M sucrose, 10 mM MgCl2 solution (S1 solution)
and layered over 3 mL 0.35 M sucrose, 0.5 mM MgCl2
solution (S2 solution) and centrifuged at 1430 × g for
5 minutes at 4°C. The clean, pelleted nuclei were re-
suspended in S2 solution and sonicated eight times
(10-s bursts at 1-minute intervals) using a 450 Branson
Sonifier and microtip probe at power setting 4. The sonic-
ate was assessed by light microscopy to certify the absence
of intact nuclei and the presence of nucleoli as dense re-
fractive bodies. The sonicated sample was layered over a
0.88 M sucrose, 0.5 mM MgCl2 solution (S3 solution) and
centrifuged for 10 minutes at 2,800 g at 4°C. The pellet
contained the nucleoli while the supernatant consisted of
the nucleoplasmic fraction. The nucleolar pellet was
washed twice with S2 solution (5 minutes at 2,000 g) and
protein extracts obtained by cell lysis buffer addition.Immunohistochemistry
Tumors were divided into half and either processed for
protein lysates (as above) or fixed in formalin for stain-
ing using specific antibodies or H&E for histological
evaluation. A paraffin-embedded tumor tissue array
(BR8013, US Biomax) containing normal and tumor
breast samples and MDA-MB-231 tumors were deparaf-
finized, rehydrated, processed for antigen retrieval, and
peroxidase quenched as described [17]. Tissues were
blocked (PBS with 1% BSA, and 0.1% Triton X-100) for
45 minutes at room temperature (RT) and incubated
with anti-pY397 FAK (1:100), or anti-NS (1:100) in
blocking buffer overnight. Biotinylated goat-anti-rabbit
IgG, Vectastain ABC Elite, and diaminobenzidine were
used to visualize antibody binding. Slides were counter-
stained with hematoxylin or methyl green. Images were
captured using an upright microscope (Olympus BX43)
with a color camera (Olympus SC100). For GFP ana-
lyses, cells were plated in coverslips, fixed with parafor-
maldehyde (PFA) (4%) for 10 minutes and cell nuclei
were visualized by incubation with 1:50,000 dilution of
Hoechst 33342 (Invitrogen). Images were sequentially
captured at 20× magnification (UPLFL objective, 1.3
NA; Olympus) using a monochrome charge-coupled
camera (ORCA ER; Hamamatsu), an inverted micro-
scope (IX81; Olympus), and Slidebook software (v5.0,
Intelligent Imaging). Images were pseudo-colored, over-
laid, merged using Photoshop (Adobe), and quantified
using Image J.
Cell cycle analyses
Cells were collected as a single cell suspension by lim-
ited trypsin treatment and fixed in 70% ethanol and
stored at −20°C overnight. Cells were incubated in 100 μl
of PBS containing DNAse-free RNAse (100 μg/mL,
Qiagen) and after 45 minutes, propidium iodide (PI,
10 μg/mL) was added prior to flow cytometry. Ana-
lyses were performed using FlowJo software (v9.5.1).
Real-time quantitative PCR analyses
RNA was extracted from FAK-WT and FAK-KD MDA-
MB-231 cells using the RNeasy Kit (Qiagen). NS and
actin (used as normalization control) were amplified
with specific primers (below). For PCR we used 480
SYBR green master mix (BioPioneer) with a LighterCycler
480 (Roche). Cycle conditions were 40 cycles of 94°C for
15 s, 56°C for 30 s, and 72°C for 30 s. The normal-
ized mRNA level was defined as DCt = (target gene)-Ct
(reference gene) and presented as fold difference between
control and test samples (DCt control-DCt test). Actin
forward 5′ GCGAGCACAGAGCCTCGCCTTTG 3′,
actin reverse 5′ ACGACGAGCGCGGCGATATCAT 3′,
NS forward 5′ TATCCATGGGGCTTACAAGG 3′ and
NS reverse 5′ CTGGACTTCGCAGAGCAAG 3′.
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Expression array data were evaluated using the online
Kaplan-Meier plotter [39]. The datasets (2014) were
from Affymetrix HG-U133A, HG-U133 Plus 2.0, and
HG-U133A 2.0 microarrays that share 22,277 probe sets
in common. Overall survival (OS) information was from
the Gene Expression Omnibus (GEO) (Affymetrix mi-
croarrays only), European Genome-Phenome Archive
(EGA), and The Cancer Genome Atlas (TCGA) data-
bases. The probe set used for PTK2 (FAK) analyses was
208820_at, NS was 217850_at, B23 was 221923_s_at and
NCL (nucleolin) was 200610_s_at. Query parameters
were: OS, split patients by median, auto-select best cut-
off, and follow-up threshold of 10 years. For OS ana-
lyses, the signal range of the probes was as follows:
PTK2 probe, 346–8042; NS probe, 1697–13661; B23
probe, 642–17106, and NCL probe, 1697–13661. The
auto-cutoff value was 2515, 1802, 3772, and 6309 for
PTK2, NS, B23, and NCL, respectively. Restriction ana-
lyses were estrogen receptor (ER) status (all), progester-
one receptor (PR) status (all), lymph node status (all),
grade (all), and intrinsic subtype (all). In total, 741 pa-
tient samples were analyzed.
Statistics
Significant difference between groups was determined
using one-way analysis of variance (ANOVA) with Tukey
post hoc analysis. Differences between paired data were
determined using the unpaired two-tailed Student’s
t-test. All statistical analyses were performed using
Prism (GraphPad Software, v5.0d). P-values <0.05 were
considered significant.
Results
FAK inhibitor reduction in breast carcinoma
anchorage-independent growth is associated with
decreased nucleostemin levels
Nanomolar concentrations of pharmacological FAK inhibi-
tors prevent 4T1 breast carcinoma growth under three-
dimensional but not two-dimensional conditions [16]. This
also occurs in mesothelioma [21] and ovarian carcinoma
cells [17-19] expressing low levels of the merlin tumor sup-
pressor protein [18,21]. The 50% inhibitory concentration
(IC50) for FAK Y397 phosphorylation in MDA-MB-231
breast carcinoma cells is approximately 0.1 μM (Additional
file 1: Figure S1A) and this is similar to results obtained
with 4T1L murine breast carcinoma cells using a different
(PND-1186, renamed VS-4718) FAK inhibitor [16].
Here, we tested the effects of FAK inhibitor (0.1 μM,
PF-271) addition on the two- and three-dimensional
growth of human breast cancer cells. No growth differ-
ences were observed after 3 days in adherent two-
dimensional culture (Figure 1A and Additional file 1:
Figure S1B). This is consistent with studies showing thatPF-271 (up to 1.0 μM) did not prevent prostate or pan-
creatic cancer cell growth in culture [37,40,41]. Although
BT474 and MDA-MB-468 colony growth in methyl-
cellulose was not affected, 0.1 μM PF-271 addition
inhibited MCF7, MDA-MB-231, and 4T1L anchorage-
independent three-dimensional colony growth (Figure 1B
and Additional file 1: Figure S1C). Interestingly, NS
knockdown also prevents three-dimensional growth
of MCF7 and MDA-MB-231 cells [31]. Immunoblot-
ting analyses revealed that whereas FAK Y397 phos-
phorylation was inhibited in all cells by 0.1 μM PF-271
treatment (Figure 1C), PF-271 reduced NS levels only in
MCF7, MDA-MB-231, and 4T1L cells (Figure 1C and D).
No PF-271-associated effects were observed on B23
(nucleophosmin) or nucleolin (Figure 1C and Additional
file 1: Figure S1D) and low NS levels were not altered
by PF-271 treatment of BT474 or MDA-MB-468 cells
(Figure 1C and D). Together, these results support a con-
nection between FAK activity and NS levels in a subset of
breast carcinoma tumor cells.
Previous studies showed that orthotopic MDA-MB-
231 and 4T1L tumor growth were inhibited by oral
administration of the FAK inhibitor VS-4718 [15]. Add-
itional analyses of tumor lysates from these experiments
revealed decreased FAK Y397 phosphorylation, reduced
NS levels, but no changes in B23 expression (Figure 1E
and F). To confirm the importance of NS expression for
MDA-MB-231 growth, two different shRNAs were
stably-expressed by puromycin selection, and resulted in
NS knockdown >75% in MDA-MB-231 cells (Figure 1G).
NS knockdown but not expression of Scr shRNA control,
prevented MDA-MB-231 colony growth in methylcellulose
but not in two-dimensional adherent culture (Figure 1H
and I). Interestingly, Kaplan-Meier analyses of a large
tumor microarray database revealed that higher FAK, NS,
and B23 mRNA levels were associated with decreased pa-
tient survival over 10 years (Additional file 2: Figure S2). As
FAK inhibition can impact NS levels in tumors, our results
support the notion that FAK and NS may be part of a sig-
naling axis promoting breast carcinoma tumor progression.
Genetic FAK inhibition decreases MDA-MB-231 growth in
methylcellulose and reduces NS protein but not mRNA
levels
To support the linkage between FAK inhibition and de-
creased NS levels, lentiviral transduction was used to
overexpress GFP or GFP fusions of FAK-WT or FAK-
KD (K454R, kinase-dead) in MCF7 cells (Figure 2A). Im-
munoblotting revealed a selective reduction in NS but
not B23 nucleolar protein levels by GFP-FAK-KD ex-
pression (Figure 2A). In a related approach, lentiviral
anti-FAK shRNA was used to knock down endogenous
FAK expression in MDA-MB-231 cells. Interestingly,
stable FAK knockdown (approximately 50%) was not
Figure 1 (See legend on next page.)
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Figure 1 Pharmacological focal adhesion kinase (FAK) inhibition selectively reduces nucleostemin (NS) levels and impacts
anchorage-independent spheroid breast carcinoma growth. (A, B) Growth of dimethyl sulfoxide (DMSO)- or PF-271 (0.1 μM)-treated
cells: MCF7, BT474, 468 (MDA-MB-468), 231 (MDA-MB-231), and 4T1L in adherent conditions for 3 days (A) or methylcellulose for 25 days (B). Values
are means expressed as percent of DMSO control. (C) Representative lysates of the indicated cells treated with DMSO or PF-271 for 3 days
and immunoblotted for pY397 FAK, total FAK, NS (light and dark exposures), B23, and actin. (D) Ratio of NS to actin levels in PF-271-treated
and control cells determined by densitometry. (E, F) Immunoblots from tumor lysates (n = 5 independent controls and 5 treated with
VS-4718) quantified by densitometry for MDA-MB-231 and 4T1L cells grown orthotopically in mice and treated with 5% sucrose (control) or 0.5
mg/kg VS-4718 [15]. Shown is the ratio of pY397 FAK to total FAK, NS to actin, and B23 to actin. The mean of vehicle-treated tumors was
set to 1. (G) Anti-NS immunoblotting of MDA-MB-231 cells with lentiviral shRNA-mediated NS knockdown (NS-1 and NS-2) compared to
scrambled (Scr) control. (H, I) Growth of MDA-MB-231 Scr, shRNA NS-1 or NS-2 cells in methylcellulose over 25 days (H) or adherent culture
over 5 days (I). For all graphs, values are means (+/− SEM, *P <0.05, **P <0.01, ***P <0.001, ****P <0.0001) of triplicate points from experiments
repeated three times.
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However, upon stable re-expression of GFP-FAK-WT
(herein termed FAK-WT) or GFP-FAK-KD (herein
termed FAK-KD) in anti-FAK shRNA-expressing MDA-
MB-231 cells, NS levels were reduced by approximately
60% in FAK-KD cells but not altered in FAK-WT cells
(Figure 2B and C). These results support the notion that
FAK activity facilitates the maintenance of NS expres-
sion in MCF7 and MDA-MB-231 cells.
By flow cytometry, GFP-FAK-KD was expressed at
slightly higher levels than GFP-FAK-WT (Figure 2D).
FAK-KD did not affect MDA-MB-231 adherent growth in
culture (Figure 2E). However, FAK-KD significantly de-
creased anchorage-independent spheroid growth (P <0.001)
(Figure 2F and G). Cell cycle analyses of FAK-WT and
FAK-KD spheroids from methylcellulose colonies revealed
a higher percentage of FAK-KD cells in G0/G1 and a
lower percentage of cells in G2 compared to FAK-WT
spheroids (Additional file 3: Figure S3). These results
support the notion that FAK activity is selectively import-
ant in promoting anchorage-independent MDA-MB-231
cell proliferation.
Immunoblotting analyses of FAK-KD spheroids revealed
decreased FAK pY397 phosphorylation and lower steady
state levels of NS but not B23 compared to FAK-WT cells
(Figure 2H). This difference was not associated with alter-
ations in NS mRNA levels as analyzed by quantitative PCR
(Figure 2I). However, addition of MG132 proteasome inhibi-
tor to FAK-KD MDA-MB-231 cells for 3 hours was suffi-
cient to restore NS levels equivalent to FAK-WT cells
(Figure 2J). As it is known that NS is subject to ubiquitina-
tion and degradation [34], our results support the hypothesis
that FAK activity is important in protecting NS protein from
proteasomal degradation and that this linkage may enable
MDA-MB-231 anchorage-independent spheroid growth.
Genetic FAK inhibition impairs orthotopic tumor growth
associated with lower tumor-associated NS
To determine whether MDA-MB-231 spheroid growth
alterations results in altered tumor growth, FAK-WT or
FAK-KD cells were orthotopically implanted into thebreast fat pad of NOD/SCID mice (Figure 3). FAK-KD
tumor volume was significantly lower compared to FAK-
WT from Day 33 to Day 57 (Figure 3A). Mice bearing
FAK-WT tumors at day 57 were larger (Figure 3B
and C) and exhibited increased spontaneous metasta-
sis from breast to lung (Figure 3D) compared to
FAK-KD-bearing mice. Immunoblotting analyses of
primary tumor lysates showed significantly decreased
FAK Y397 phosphorylation and lower NS levels in
seven independent FAK-KD tumors compared to FAK-
WT samples (Figure 3E and F). Importantly, tumor levels
of other nucleolar proteins such as B23 or nucleolin, re-
spectively, were not different (Figure 3E and F). NS ex-
pression in FAK-WT tumors was higher than FAK-KD
MDA-MB-231 tumors as confirmed by immunohisto-
chemical staining of paraffin sections (Figure 3G). Ana-
lyses of FAK-IPs from FAK-WT and FAK-KD tumor
lysates revealed the enhanced association of B23 with
FAK-WT, but not with FAK-KD (Figure 3H). As B23 is a
binding partner of NS in the nucleolus [42], we speculate
that FAK interactions with B23, possibly in a sub-
compartment such as the nucleolus, may facilitate NS
regulation impacting breast tumor growth.
Active FAK localization to the nucleolus in breast
cancer cells
In adherent cells, FAK localizes to sites of integrin adhe-
sion. However, upon pharmacological FAK inhibition,
conditions of cellular stress, or analyses of cells under
anchorage-independent conditions, FAK nuclear distri-
bution increases [22]. Nuclear FAK can alter gene ex-
pression and provide a kinase-independent survival
signal to cells [23,24]. To determine the intracellular dis-
tribution of FAK in adherent and suspended MDA-MB-
231 cells, biochemical fractionation was performed
(Figure 4A). Cytoplasmic, nucleoplasmic (nuclear extract
minus nucleolus), and purified nucleoli fractions were
analyzed by immunoblotting for GFP-FAK, activated
FAK (pY397 FAK phosphorylation), Lamin B (nucleo-
plasmic marker), GAPDH (cytoplasmic marker), and
B23 (nucleolar marker) (Figure 4B). The majority of
Figure 2 (See legend on next page.)
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Figure 2 Genetic focal adhesion kinase (FAK) inhibition impacts MDA-MB-231 spheroid growth and lowers nucleostemin (NS) protein
levels. (A) MCF7 cells over-expressing green fluorescent protein (GFP), GFP-FAK-wild-type (WT), or GFP-FAK-kinase-dead (KD) were analyzed for
pY397 FAK, total FAK, NS, B23, and actin levels by immunoblotting. (B) MDA-MB-231 cells were transduced with lentiviral scrambled (Scr) or anti-human
FAK shRNA. Murine GFP-FAK-WT (FAK-WT) or GFP-FAK-KD (FAK-KD) were stably re-expressed in FAK shRNA MDA-MB-231 cells. Immunoblotting of total
FAK, NS, and actin. (C) Densitometry of NS to actin ratios. Values are means ± SD of triplicate points (*P <0.05) from three independent experiments.
(D) Histogram of GFP fluorescence as determined by flow cytometry. (E) Adherent growth of FAK-WT and FAK-KD MDA-MB-231 cells. Values are means
(± SEM) of triplicate points from two independent experiments. (F) Representative colony growth in methylcellulose (31 days) of FAK-WT and FAK-KD
MDA-MB-231 cells. Scale is 0.5 mm. (G) Colony number of FAK-WT and FAK-KDMDA-MB-231 cells. Values aremeans ± SEM of triplicate points (***P<0.001)
from two independent experiments. (H) Immunoblotting for pY397 FAK, total FAK, NS, B23, and actin in FAK-WT and FAK-KD MDA-MB-231 cells. (I)
qPCR analyses of NS mRNA levels from FAK-WT and FAK-KD MDA-MB-231 cells. Fold change as compared to actin (± SEM) is shown. Data represent
triplicate points from three independent experiments. N.S., no significant difference. (J) NS, B23, and actin immunoblotting analyses from FAK-WT and
FAK-KD MDA-MB-231 cells cultured in methylcellulose for 3 days, and treated or not 3 hours prior to cell lysis (as indicated) with MG132 proteasome
inhibitor (40 μM).
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with lower levels detected in the nucleoplasmic fraction.
Both FAK-WT and FAK-KD were present in the nucleo-
plasm and this did not change upon holding MDA-MB-
231 cells in suspension for 4 h (Figure 4B). Interestingly,
FAK-WT phosphorylated at Y397 was associated with
purified nucleoli from adherent cells and the amount of
nucleolar and Y397 phosphorylated FAK-WT increased
upon holding MDA-MB-231 cells in suspension for 4 h
(Figure 4B and C). Surprisingly, nucleoli from suspended
cells contained only low levels of FAK-KD that was not
phosphorylated (Figure 4B and C). These results support
the hypothesis that FAK activity is important in promot-
ing its nucleolar localization.
To determine if nucleolar FAK localization could be
visualized in intact cells, adherent GFP-FAK-WT cells
were imaged by confocal microscopy. Strong GFP-FAK-
WT fluorescence was detected in a sub-compartment of
the nucleus (Figure 4D, arrows and Additional file 4:
Figure S4A). GFP-FAK-KD or expression of GFP alone
in MDA-MB-231 cells did not exhibit this pattern of
nucleolar localization as did GFP-FAK-WT (Additional
file 4: Figure S4A and B). To determine if nucleoli-
localized active FAK could be detected in breast tumors,
a tissue micro-array containing normal breast and inva-
sive ductal carcinoma (IDC) samples were stained with a
monoclonal antibody to FAK pY397 (Figure 4E). Previ-
ous studies have shown that FAK expression is low in
normal breast tissue and increases as a function of
tumor grade and stage [7]. We find that normal breast
tissue is weakly stained for pY397 FAK and the ma-
jority of IDC samples exhibit strong cytoplasmic or
membrane-associated pY397 FAK staining (Figure 4E).
However, in a subset of IDC tissues, strong nuclear-
and nucleoli-localized pY397 FAK staining was de-
tected (Figure 4E, arrows). These results support a
signaling role for nucleolar-associated FAK in breast
carcinoma cells that is distinct from a canonical in-
tegrin adhesion-dependent mechanism.Akt activation can prevent NS loss by FAK inhibition
To determine if a complex between FAK and NS could
be detected, MDA-MB-231 cells were transfected with
GFP or GFP-NS (N-terminal fusion). GFP-NS exhibited
sub-compartment localization within nuclei, whereas
GFP was distributed throughout cells (Figure 5A).
Co-immunoprecipitation assays with antibodies to GFP
revealed a complex of mTOR, FAK, and Akt with GFP-
NS and not GFP alone (Figure 5B). To determine if
FAK inhibition alters Akt or mTOR activation in breast
carcinoma cells, lysates of MCF7, BT474, MDA-MB-
468, MDA-MB-231, and 4T1L treated with DMSO
(control) or 0.1 μM PF-271 FAK inhibitor for 3 days
were evaluated by immunoblotting (Figure 5C). BT474
and MDA-MB-468 cells maintained elevated phosphor-
ylated serine-473 (pS473) Akt in the presence of PF-
271 (Figure 5C). This is consistent with PIK3CA and
PTEN mutations in BT474 and MDA-MB-468 cells, re-
spectively (Table 1). However, reduced pS473 Akt phos-
phorylation occurred in MCF7, MDA-MB-231, and
4T1L cells with PF-271 addition (Figure 5C). In MDA-
MB-231 and 4T1L cells, 0.1 μM PF-271 also decreased
serine-65 (pS65) phosphorylation of 4E-binding protein
1 (4E-BP1) [43], a translation repressor protein and tar-
get the mTOR complex (Figure 5C, #). In MDA-MB-
468 cells, PF-271 did not reduce either Akt or 4E-BP1
phosphorylation (Figure 5C) and these cells were
insensitive to PF-271-mediated regulation of NS
(Figure 1C). In MDA-MB-231 tumor lysates, genetic FAK
inhibition (FAK-KD) was associated with decreased
pS65 4E-BP1 phosphorylation (Figure 5D). These re-
sults support the notion that FAK may stimulate Akt-
mTOR pathway activation that may act to stabilize NS
protein levels.
To test the importance of Akt activity in this linkage,
constitutively-active Akt (myristylated-Akt, Akt*) was
stably expressed in FAK-WT and FAK-KD MDA-MB-
231 cells. Enhanced Akt activity was confirmed by el-
evated pS473 Akt phosphorylation in both FAK-WT
Figure 3 Focal adhesion kinase (FAK)-kinase-dead (KD) MDA-MB-231 tumors are small with low nucleostemin (NS) levels. (A) Mean
volume of FAK-WT (black, n = 8) and FAK-KD (gray, n = 9) MDA-MB-231 cells grown as orthotopic breast tumors in NOD/SCID mice from day 33
to 57 (± SEM, *P <0.05, **P <0.01; ***P <0.001). (B) Final FAK-WT or FAK-KD tumor mass at day 57. Values are means (± SEM, ***P <0.001).
(C) Representative images of FAK-WT and FAK-KD tumors at day 57 (scale 0.5 cm.) (D) Mean number of spontaneous breast to lung metastases as
visualized by fluorescence (+/− SEM, * P <0.05). (E) Protein lysates from FAK-WT (n = 7) or FAK-KD (n = 7) MDA-MB-231 tumors analyzed
by immunoblotting for pY397 FAK, total FAK, nucleolin, NS, B23, and actin. (F) Immunoblots in panel E were quantified by densitometry.
Values (from seven tumors) are means (± SEM) and displayed as the ratio of FAK pY397 to total FAK, nucleolin to actin, NS to actin, and B23 to actin.
FAK-WT values for each comparison were set to 1 (*P <0.05, **P <0.01). (G) Representative anti-NS immunohistochemical staining (diaminobenzidine,
DAB) of FAK-WT and FAK-KD tumors. Tumors were counterstained with methyl green (scale 100 μm). (H) FAK immunoprecipitates (IPs) from three
FAK-WT and three FAK-KD tumors were analyzed for associated B23 nucleolar protein by immunoblotting.
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pression resulted in elevated steady-state NS levels
and increased 4E-BP1 phosphorylation in FAK-KD
cells. Akt* expression was sufficient to rescue FAK-
KD MDA-MB-231 colony growth in methylcellulose
equal to control FAK-WT levels (Figure 5F). These
results demonstrate that activated Akt expression canpromote colony growth and prevent NS loss associ-
ated with FAK inhibition.
Rapamycin lowers NS levels in MDA-MB-468 cells with
activated Akt
PF-271-mediated FAK inhibition did not alter NS levels
in MDA-MB-468 cells that exhibit high levels of Akt
Figure 4 (See legend on next page.)
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Figure 4 Active focal adhesion kinase (FAK) associates with nucleoli in breast carcinoma cells. (A) Cell fractionation protocol for
cytoplasmic, nucleoplasmic, and nucleolar isolation. (B) FAK pY397, total FAK, Lamin B, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and
B23 immunoblotting analyses of FAK-WT and FAK-KD reconstituted MDA-MB-231 fractionation from adherent (0 h) and cells held in suspension
for 4 h. FAK-WT and FAK-KD were detected within cytoplasmic and nucleoplasmic fractions. Greater FAK-WT levels and Y397 phosphorylated FAK
were associated with purified nucleoli compared to FAK-KD. (C) Ratio of GFP-FAK to B23 levels determined by densitometry: means ± SD from
three independent experiments with FAK-WT at 0 h set to 1 (*P <0.05, **P <0.01). (D) Representative confocal microscopy of green fluorescent
protein (GFP)-FAK wild-type (WT) fluorescence and nuclei staining. Merge shows Hoechst (blue) and nucleolar GFP-FAK-WT (green) localization
(arrows). Medial confocal section (scale 50 μm). (E) Representative pY397 FAK staining in paraffin-embedded normal and human breast carcinoma
tumors. Normal breast contains little pY397 FAK signal; invasive ductal carcinoma (IDC) exhibits both cytoplasmic (right) and nuclear-associated
anti-pY397 FAK staining (brown). Inset, higher magnification shows punctate pY397 FAK staining (arrows) within nuclei. Slides were counterstained
with hematoxylin (scale 25 μm).
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MB-468 cells has revealed mutations in the phosphatase
and tensin homolog (PTEN) protein that acts as a nega-
tive regulator of the Akt signaling pathway (Table 1). To
evaluate the importance of mTOR activation in main-
taining NS protein levels, MDA-MB-468 cells were
treated with rapamycin (0.1 μM for 1 h), an inhibitor of
mTOR complex (Figure 5G). Rapamycin treatment de-
creased NS levels and reduced 4E-BP1 phosphorylation.
This was independent of effects on FAK or Akt phos-
phorylation. These results support the importance of
mTOR activity in maintaining NS levels in MDA-MB-
468 cells.
Discussion
FAK inhibitors are being evaluated in several clinical
trials with an underlying rationale that effects are medi-
ated through alterations in both tumor and stromal cell
function [6]. FAK inhibitory effects on tumor cells in-
volve the prevention of cell motility and invasion
in vitro as well as tumor growth and metastasis in
mouse models. FAK inhibitor administration can slow
tumor growth and trigger increased tumor cell apop-
tosis in vivo [15,37]. Although this may be due in part
to angiogenesis prevention [44], studies are beginning
to uncover selective roles for FAK signaling when
tumor cells are grown as spheroids in vitro [16-19]. Im-
portantly, nanomolar sensitivity to FAK inhibition is
not observed using standard monolayer cell culture.
However, some tumor cells exhibit insensitivity as
three-dimensional spheroids to micromolar FAK inhibi-
tor levels [18]. Elucidating the molecular basis for these
differential effects will provide fundamental knowledge
of how best to apply FAK inhibitor treatment in clinical
settings.
Herein, we identify a new linkage between FAK activity
and the nucleolar protein, nucleostemin (NS), in the
regulation of anchorage-independent spheroid and
orthotopic breast carcinoma growth as tumors. Genetic
or pharmacological FAK inhibition was associated with
decreased NS levels but not other nucleolar proteinssuch as B23 (nucleophosmin) or nucleolin in cell culture
and in tumors. NS knockdown prevented MDA-MB-231
cell growth as spheroids but was not essential for growth
in two-dimensional culture. FAK inhibition did not alter
NS mRNA levels and proteasomal inhibition stabilized
NS upon FAK inhibition. These results support the
importance of FAK activity in protecting NS protein
from proteasomal degradation and we hypothesize that
this may enable MDA-MB-231 anchorage-independent
growth. However, NS over-expression in MDA-MB-231
cells did not promote anchorage-independent growth in
the presence of FAK inhibition (I. Tancioni, unpub-
lished) and cells expressing high basal NS levels (MDA-
MB-231 and 4T1L) are not resistant to FAK inhibitor
growth inhibition. Thus, high NS levels are not predict-
ive of FAK inhibitor resistance.
Nevertheless, it is intriguing that both FAK and NS
can control common stem cell-like properties of tumor
cells such as anchorage-independent growth [21,31].
Since tumor cells are not making canonical focal adhe-
sions as three-dimensional spheroids, we investigated
the distribution of active FAK by cellular fractionation.
An increased percentage of active GFP-FAK-WT was as-
sociated with purified nucleoli following cell suspension
for 4 hours. Surprisingly, although GFP-FAK-KD was
present in the nucleoplasmic fraction, only low levels of
GFP-FAK-KD were found in purified nucleoli. The
mechanism(s) directing active FAK to the nucleolus re-
main under investigation. For FAK-WT, nucleolar
localization was detected by confocal microscopy and a
subset of invasive ductal breast carcinoma tumors exhib-
ited nucleolar staining with antibodies to pY397 FAK.
These results are consistent with phosphoproteomic
studies showing that Y397 FAK was elevated in stem cell
spheroid clusters [45] and that nuclear active FAK is as-
sociated with a poor prognosis in human colorectal can-
cer [46]. As FAK-WT co-immunoprecipitates with B23,
and NS forms a complex with B23 in the nucleolus [42],
our studies support a signaling role for active nucleolar-
associated FAK that is distinct from a canonical integrin
adhesion linkage mechanism.
Figure 5 (See legend on next page.)
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Figure 5 Activated Akt can prevent nucleostemin (NS) loss by focal adhesion kinase (FAK) inhibition; connections to mammalian
target of rapamycin (mTOR) as analyzed by pS65 4E-BP1 phosphorylation and rapamycin inhibition. (A) Representative fluorescence
confocal microscopy of MDA-MB-231 cells transfected with green fluorescent protein (GFP) or GFP-NS (24 h) (scale 50 μm). (B) Anti-GFP
antibody co-immunoprecipitation (IP) of MDA-MB-231 cells transfected with GFP or GFP-NS. Shown is immunoblotting (IB) for GFP, mTOR,
FAK, and Akt. (C) Lysates of dimethyl sulfoxide (DMSO)- or PF-271-treated (0.1 μM, 72 h) from adherent cells and immunoblotted for pS473
Akt, total Akt, pS65 4E-BP1, and actin. Reduction in pS473 Akt and pS65 4E-BP1 in PF-271-treated MDA-MB-231 and 4T1L cells (lanes indicated
by #). (D) FAK-wild-type (WT) and FAK-kinase-dead (KD) MDA-MB-231 tumor lysates were immunoblotted for pS65 4E-BP1 and quantified by
densitometry. Values are means (± SEM) and displayed as the ratio of pS65 4E-BP1 to actin. FAK-WT values were set to 1 (*P <0.05). (E) Stable
expression of myristoylated - activated Akt (Akt*) in FAK-WT and FAK-KD MDA-MB-231 cells. Lysates were immunoblotted for pS473 Akt, total
Akt, NS, B23, pS65 4E-BP1 and actin. (F) Colony formation of control (CTRL) and Akt*-expressing in FAK-WT and FAK-KD MDA-MB-231
cells. Values are means (± SEM, **P <0.01) of triplicate points. (G) MDA-MB-468 cells treated with PF-271 or rapamycin for 1 h (adherent)
and lysates evaluated by pY397 FAK, total FAK, NS, B23, pS473 Akt, total Akt, pS65 4E-BP1, and actin immunoblotting. Blots are from one representative
experiment repeated three times.
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nucleolar sites in MDA-MB-231 cells and formed a
complex with FAK, Akt, and mTOR as determined by
co-immunoprecipitation. Interestingly, mTOR Complex
1 can localize to the nucleolus and nuclear Akt interacts
with B23, leading to protection from proteolytic cleavage
and enhancement of cell survival [47,48]. This led us to
explore whether connections may exist between FAK,
Akt, and mTOR in the regulation of NS levels. Indeed,
expression of constitutively-active Akt promoted colony
growth and stabilized NS levels in the presence of inhib-
ited FAK. Further, rapamycin inhibition of mTOR low-
ered NS levels in PTEN-mutated MDA-MB-468 breast
carcinoma cells. These results support a FAK to Akt to
mTOR signaling linkage in the regulation of NS levels.
As elevated FAK expression in breast cancer is associ-
ated with a triple-negative cell phenotype [49], our re-
sults support a model whereby FAK activity-mediated
modulation of NS levels may be part of a mesenchymal-
or stem cell-associated regulatory circuit. Combinational
use of FAK and PI3K-mTOR inhibitors [50] may have
additive effects in breast cancers that show resistance to
standard therapies.
Conclusions
This study shows that FAK activity regulates nucleos-
temin (NS) levels, a nucleolar protein involved in pro-
moting breast tumor growth. FAK activity and NS are
selectively required for anchorage-independent MDA-
MB-231 spheroid growth and cell fractionation ana-
lyses revealed active FAK association with nucleoli
upon holding MDA-MB-231 cells in suspension. Acti-
vation of Akt stabilized NS levels and promoted
anchorage-independent growth in the presence of
inactivated FAK. As rapamycin lowered NS levels in
PTEN-mutated MDA-MB-468 breast carcinoma cells,
our studies support a role for nucleolar-associated
FAK signaling and Akt-mTOR activation in the main-
tenance of NS protein expression. Reduction in NSlevels may serve as a protein biomarker of FAK inhibi-
tor effectiveness in breast cancer therapy.
Additional files
Additional file 1: Figure S1. Pharmacological focal adhesion kinase
(FAK) inhibition prevents breast carcinoma growth in methylcellulose but
not in adherent conditions. (A) Dose-dependent inhibition of FAK pY397
phosphorylation by PF-271. MDA-MB-231 cells were treated with vehicle
(dimethyl sulfoxide (DMSO)) or increasing concentrations of PF-271 for 1
hour and lysates immunoblotted for pY397 FAK, total FAK, and actin. The
ratio between pY397FAK and FAK of DMSO was set to 1. (B) The indicated
breast carcinoma cells were grown in presence of DMSO or PF-271 (0.1 μM)
for 3 days and imaged by phase contrast microscopy. Scale is 100 μm.
(C) The indicated breast carcinoma cells were grown in presence of
DMSO or PF-271 (0.1 μM) for 25 days in methylcellulose and imaged
by phase contrast microscopy. Scale is 500 μm. (D) Lysates of DMSO- or
0.1 μM PF-271-treated (3 days) MCF7, BT474, 468 (MDA-MB-468), 231
(MDA-MB-231) cells and immunoblotted for pY397 FAK, total FAK,
nucleolin, and actin.
Additional file 2: Figure S2. Association of focal adhesion kinase (FAK),
nucleostemin, and B23 mRNA levels with breast cancer patient overall
survival. Kaplan-Meier analyses of FAK, nucleostemin, B23, and nucleolin
mRNA levels in 741 patient samples. High (red) versus low (black) mRNA
expression shows overall patient survival over 120 months. Log-rank
P-values for significance are shown (inset).
Additional file 3: Figure S3. Focal adhesion kinase- (FAK)-kinase-dead
(KD) MDA-MB-231 cells show higher percentage of cells in G0/G1 phase
than wild-type (WT)-FAK cells. FAK-WT and FAK-KD MDA-MB-231
cells cultured in methylcellulose for 3 days were collected, stained
with propidium iodide, and analyzed by flow cytometry. Representative
histogram of cell cycle analyses and percentage of cells in Sub-G1, G0/G1, S,
and G2 phases of the cell cycle as analyzed by FlowJo software.
Additional file 4: Figure S4. Green fluorescent protein-focal adhesion
kinase-wildtype (GFP-FAK-WT) nucleolar localization. (A) Representative
confocal microscopy images of re-expressing GFP-FAK-WT and
GFP-FAK-kinase-dead (KD) MDA-MB-231 cells (Hoechst nuclear stain,
blue) reveal nucleolar GFP-FAK-WT localization (arrows). GFP-FAK-KD
is primarily cytoplasmic in the confocal image. (B) Representative
confocal images of MDA-MB-231 expressing GFP-FAK-WT or GFP.
Scale is 50 μm.
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